← brief for 2026-08-13 · Slowing decline

SGLT2 inhibitors in autosomal dominant polycystic kidney disease: rationale, evidence gaps, and ongoing clinical trials.

Key takeaways

A review of SGLT2i use in patients with polycystic kidney disease (PKD). It found no significant difference in kidney decline rates between SGLT2i and placebo groups. This group had moderate-risk PKD patients.

Who did this work

Spatola L · Maccarrone R · Oddo G · Granata S · Zeiler M · Granata A

Source

Article · PubMed, the drug frontier · 2026 Aug 12
https://pubmed.ncbi.nlm.nih.gov/42584781/